Clinical Trial Update: A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease [Phase 1]

View source ↗

Summary

This Phase 1 randomized, double-blind, placebo-controlled study evaluated safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamic response o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• BAN2401

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED